

Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB on nucleos(t)ide analogues

T Evans¹, L Bussey¹, SL Teo², A Tria², A Brown³, R Mehta¹, K Anderson¹, A Vardeu¹, WL Chuang⁴, CY Chen⁵, YS Lim⁶, WY Tak⁷, K Agarwal⁸, S Ryder⁹, J Heo¹⁰, BK Jang¹¹, SH Ahn¹², GH Lo¹³, KC Tseng¹⁴, SK Yoon¹⁵, WW Su¹⁶, CT Hu¹⁷, E Barnes³ ¹Vaccitech, ²ICON, ³Oxford University, ⁴Kaohsiung Medical University Hospital, ⁵Chia-Yi Christian Hospital, ⁶Asan Medical Center, ⁷Kyungpook National University Hospital, South Korea; ⁸King's College Hospital NHS Foundation Trust, ⁹Nottingham University Hospitals NHS Trust, ¹⁰Pusan National University Hospital, ¹¹Keimyung University Dongsan Hospital, ¹²Yonsei University College of Medicine, ¹³E-Da Hospital, ¹⁴Dalin Tzu Chi General Hospital, ¹⁴Changhua Christian Hospital, ¹⁷Hualien Tzu Chi Hospital

INTRODUCTION: Induction of a CD8+ T cell response to HBV is considered to be a needed mechanism to achieve a functional cure of chronic hepatitis B (CHB). The highest magnitude CD8+ T cell responses achieved to date in man have used replication incompetent adenoviral vectors followed by attenuated poxvirus vector boosts.

AIM: The goal of this study is to assess the immunogenicity and activity on cccDNA of VTP-300 (as measured by surface antigen reduction) as monotherapy and when combined with low-dose checkpoint inhibition, in virally suppressed, chronic hepatitis B patients.

METHODS: Vaccitech has developed an HBV immunotherapeutic using a chimpanzee adenoviral vector (ChAdOx1-HBV) and a heterologous Modified vaccinia Ankara boost (MVA-HBV), both encoding the inactivated polymerase, core, and the entire S region from a consensus genotype C virus (VTP-300). A Phase 1b/2a trial has enrolled 55 patients with virallysuppressed CHB (on antivirals for a minimum of one year with viral load undetectable and HBsAg <4,000 IU) in Taiwan, South Korea and the UK (NCT047789). Hepatitis B specific efficacy and immunologic parameters were followed.

As of May 2022, the study had closed recruitment, having exceeded enrolment at n=55 patients. An amendment closed Groups 1 and 4 early due to interim HBsAg data. Visits were conducted at days 0, 7, 28, 35 and months 3, 6 and 9. HBsAg data shown were collected through May 9, 2022. Individual plots show results for those patients with data through at least month 3.

Immunologic assays are performed with peptide pools encompassing core, Pol (4 pools) pre-S1, pre-S2, S for the gamma IFN ELISpot and 4 pools (Core, Pol1, Pol2, S) for the ICS assay. All assays are short, 6-hour to overnight stimulations without *in vitro* expansion. The ICS used the following phenotypic and activation markers: CD3, CD4, CD8, IFNg, IL-2, TNF-α, CCR7, CD45RO, CD107, CD154.

Construct Design



HBV002 Phase 1b/2a (South Korea, Taiwan, UK)

• On effective antiviral treatment for one year • HBV DNA <40 copies/mL HBsAg <4,000 IU/mL

Group	Age (Yrs)	Gender (M:F)	Total participants	Through D 35	Through Mo 3	Through Mo 6	Through Mo 9
1	52.6 ± 6.8	8:1	10 (9)*	9	9	9	9
2	53.3 ± 6.7	15:3	18	13	10	8	6
3	49.8 ± 8.3	11:7	18	14	11	8	6
4	49.9 ± 15.4	7:2	9	9	9	7	5

early discontinuation

• To date no vaccine-related SAEs Two patients with mild, rapidly resolving transaminitis • Local reactions have been mild or moderate

Solicited Symptoms by Maximum-Reported Severity (data cutoff: 26 April 2022)

	Any Grade	Grade 1	Grade 2	Grade 3	Grade 4			
	Graue	Grade I	Graue 2	Grade 5	Graue 4			
Participants reporting (out of n=43 dosed)								
Any solicited symptom	38	26	11	1	0			
Any local symptom	35	27	8	0	0			
Pain	33	26	7	0	0			
Redness	2	2	0	0	0			
Swelling	5	4	1	0	0			
Warmth	16	13	3	0	0			
Any systemic symptom	33	24	8	1	0			
Chills	6	5	1	0	0			
Fatigue	18	14	3	1	0			
Fever	11	10	1	0	0			
Headache	14	12	2	0	0			
Joint Ache	16	10	6	0	0			
Malaise	18	13	4	1	0			
Muscle Ache	29	23	5	1	0			
Nausea	8	6	2	0	0			
Notes: Includes reactogenicity from both doses of VTP-300. Participants are included at most once per row.								

Full length surface (including Pre-S1, Pre-S2, modified polymerase, core) Consensus genotype (Proprietary promoters

Study Design

Group 1 (N=10) MVA-HBV [1 x 10⁸ pfu]; MVA-HBV [1 x 10⁸ pfu]


Group 2 (N=18) ChAdOx1-HBV [2.5 x 10¹⁰ vp]; MVA-HBV [1 x 10⁸ pfu]


Group 3 (N=18) MVA-HBV [1 x 10⁸ pfu] + LD nivolumab [0.3 mg/kg]

Group 4 (N=9) ChAdOx1-HBV [2.5 x 10¹⁰ vp]; ChAdOx1-HBV [2.5 x 10¹⁰ vp] + LD nivolumab [0.3 mg/kg]; MVA-HBV $[1 \times 10^8 \text{ pfu}] + \text{LD}$ nivolumab [0.3 mg/kg]


Major enrollment criteria

Safety





A. Responses were most pronounced in Group 2, the heterologous prime-boost arm without nivolumab. Despite the difference in HBsAg responses in Group 3 and 4, the data to date show no major difference in peripheral blood T cell responses. Liver aspirates were not performed.



all encoded antigens

double positive (not shown)

Shown are the correlations between the magnitude of the T cell response at Day 35 (peak time point) and HBsAg declines, but dataset is still small. Correlations trended in the positive direction for CD8, but not CD4



CONCLUSIONS

- VTP-300 as monotherapy and in combination with LD nivolumab was safely administered, with no treatment-related SAEs, and infrequent transient transaminitis
- Significant, durable reductions of HBsAg were seen in patients in the VTP-300 monotherapy group (Group 2):
- 3 patients had 0.7, 0.7 and 1.4 log₁₀ declines 2 mos post last dose
- These dramatic declines are persisting in all 3 patients at latest follow-up 5 or 8 months after the last dose of VTP-300
- These 3 patients had baseline HBsAg under 50 IU/mL, implying better response in patients with low baseline HBsAg
- For the first 8 patients who received VTP-300 with a single low dose of nivolumab at the time of the booster dose (Group 3), the mean reduction in HBsAg was over 1 log₁₀ at 6 months
- This effect persisted with a mean decline of 1.15 log₁₀ at 8 months after the last dose
- Effect most prominent with starting values HBsAg < 1,000 IU/mL
- One patient in group 3 developed a non-detectable HBsAg level, which continued 8 months after last dose
- The lowering of HBsAg persisted until the last measurement in all patients with >0.5 log₁₀ reduction. This compares favorably to the lack of durability seen with direct acting agents to date
- No reductions $\geq 1 \log_{10}$ were seen in Group 1 patients who received 2 doses of MVA-HBV, or in patients who received low-dose nivolumab with both doses of VTP-300 (Group 4). These groups were discontinued after interim analysis
- A robust T cell response against all encoded antigens is observed following VTP-300, notable for marked CD8+ T cell predominance, which had never been achieved by any other immunotherapeutic
- A trial to look at timing of low dose nivolumab and additional doses of the MVA boost component of VTP-300 has been implemented, with first patient dosed expected by Q3 2022 (NCT05343481)
- These results portend well for the collaborative study with Arbutus 729 siRNA, in which HBsAg is expected to be lowered to <100 IU/mL in the majority of the patients prior to receiving VTP-300

TRIAL SITES RECRUITING PATIENTS; Kaohsiung Medical University Chung-Ho Memorial Hospital W-L Chuang); Asan Medical Center (Y-S Lim); King's College Hospital NHS Foundation Trust (K Agarwal), Nottingham University Hospitals NHS Trust (S Ryder); Pusan National University Hospital (J Heo); Keimyung University Dongsan Hospital (B Jang); Kyungpook National University Hospital (W. Tak); Yonsei University College of Medicine (S Ahn), Chia-Yi Christian Hospital C-Y Chen); E-Da Hospital (G-H Lo); Dalin Tzu Chi General Hospital (K-C Tseng)

REFERENCES: Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. Vaccines. 2020 Apr 14;8(2).

tom.evans@vaccitech.co.uk; ellie.barnes@ndm.ox.ac.uk